30 April 2020 
EMA/CHMP/54432/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Sovaldi 
sofosbuvir 
On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Sovaldi. 
The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC. 
The CHMP adopted an extension to the indication for Sovaldi as follows:2 
Sovaldi is indicated in combination with other medicinal products for the treatment of chronic 
hepatitis C (CHC) in adult and paediatric patients in adolescents aged 312 to <18 years and 
above. 
The CHMP also recommended the addition of a new 200 mg strength for the film-coated tablets and the 
introduction of a new pharmaceutical form, coated granules, which will be available in 150 mg and 
200 mg strengths.  
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
